Biocon signs commercialization agreement with Zentiva in Europe

24 Nov 2022 , 09:15 AM

Biocon Limited, an innovation-led global biopharmaceutical company, announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of Liraglutide, a drug-device combination suggested for the treatment and management of Type 2 diabetes and obesity.

Under the terms of this agreement, Biocon will be in charge of manufacturing and supplying Liraglutide to Zentiva for commercialization in 30 European countries. Biocon will also retain the right to commercialise this product in the region under its own brand.

Zentiva has a long history of producing branded generics in a variety of therapeutic areas, including diabetes, cardiology, respiratory, and oncology. Zentiva is rapidly expanding its reach in Europe and beyond, thanks to a commitment to R&D and four flagship manufacturing facilities in Bucharest, Prague, and Ankleshwar.

At around 9.17 AM, Biocon was trading at Rs281.35 up by 0.45% from its previous closing of Rs280.10 on the BSE.

For feedback and suggestions, write to us at [e-mail]